abrdn World Healthcare Fund outperformed its custom benchmark, driven by strong performances from uniQure, Oculis Holding, and New Amsterdam Pharma Company. Global equity markets dipped slightly, but optimism rose due to Trump's election win and resilient economic data, despite concerns over China and geopolitical risks. New positions in Humana, Tempus AI, Oxford Biomedica, and Exact Sciences were established, while Illumina, Edwards Lifesciences, and Acadia Healthcare were sold. Focus remains on diversifying the portfolio with high-quality businesses to withstand volatility, with a favorable long-term outlook for healthcare due to demographic trends.

abrdn World Healthcare Fund Q4 2024 Commentary (NYSE:THW)

The abrdn World Healthcare Fund outperformed its custom benchmark in Q4 2024, driven by strong performances from companies like uniQure, Oculis Holding, and New Amsterdam Pharma Company. Despite a slight dip in global equity markets, the fund's performance was bolstered by positive economic data and optimism following Trump's election win. The fund diversified its portfolio by adding positions in Humana, Tempus AI, Oxford Biomedica, and Exact Sciences, while reducing holdings in Illumina, Edwards Lifesciences, and Acadia Healthcare. The focus remains on investing in high-quality healthcare businesses to withstand market volatility.